156339-46-7

Basic information

• Product Name: 1-Piperazineethanol,-alpha-,-alpha--dimethyl-(9CI)
• Synonyms: 1-Piperazineethanol,-alpha-,-alpha--dimethyl-(9CI);2-METHYL-1-PIPERAZIN-1-YLPROPAN-2-OL;alpha,alpha-Dimethyl-1-piperazineethanol;NSC 86969;EOS-62014
• CAS NO: 156339-46-7
• Molecular Formula: C₈H₁₈N₂O
• Molecular Weight: 158.24
• Product Categories: PIPERIDINE
• Mol File: 156339-46-7.mol
• Article Data: 4

Chemical Properties

• Melting Point: 80.2-80.5 °C(Solv: hexane (110-54-3))
• Boiling Point: 262℃
• Flash Point: 112℃
• Appearance: /
• Density: 0.978
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 15.09±0.29(Predicted)
• CAS DataBase Reference: 1-Piperazineethanol,-alpha-,-alpha--dimethyl-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Piperazineethanol,-alpha-,-alpha--dimethyl-(9CI)(156339-46-7)
• EPA Substance Registry System: 1-Piperazineethanol,-alpha-,-alpha--dimethyl-(9CI)(156339-46-7)

Safety Data

• Hazardous Substances Data: 156339-46-7(Hazardous Substances Data)

Usage

General Description

1-Piperazineethanol, alpha,alpha-dimethyl-(9CI) is a chemical compound with the molecular formula C8H18N2O. It is a tertiary amine that contains a piperazine ring and an ethanol group. 1-Piperazineethanol,-alpha-,-alpha--dimethyl-(9CI) is commonly used as a pharmaceutical intermediate and a building block in the synthesis of various drugs. It is also utilized in organic chemistry as a reagent for the preparation of other organic compounds. Due to its chemical structure and properties, it is important to handle this compound with caution and follow proper safety procedures in its handling and storage.

Upstream product

• 110-85-0 piperazine 
• 558-42-9 3-chloro-2-methylpropan-2-ol 
• 1267341-14-9 4-(2-hydroxy-2-methyl-propyl)-piperazine-1-carboxylic acid tert-butyl ester 
• 558-30-5 2-methyl-1,2-epoxypropane 

Relevant articles and documents

-

-

Inhibitors of Protein Tyrosine Kinase Activity

This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling. The invention also provides compounds, compositions and methods for treating cell proliferative diseases and conditions and ophthalmic diseases, disorders and conditions.

PHARMACEUTICAL COMPOUNDS

Fused pyrimidines of formula (I); wherein A represents a thiophene or furan ring; n is 1 or 2; R1 is a group of formula (II); wherein m is 0 or 1; R30 is H or C1-C6 alkyl; R4 and R5 form, together with the N atom to which they are attached, a 5- or 6-membered saturated N-containing heterocyclic group which includes 0 or 1 additional heteroatoms selected from N, S and O, which may be fused to a benzene ring and which is unsubstituted or substituted; or one of R4 and R5 is alkyl and the other is a 5- or 6-membered saturated N-containing heterocyclic group as defined above or an alkyl group which is substituted by a 5- or 6-membered saturated N-containing heterocyclic group as defined above; R2 is selected from formula (a); wherein R6 and R7 form, together with the nitrogen atom to which they are attached, a morpholine, thiomorpholine, piperidine, piperazine, oxazepane or thiazepane group which is unsubstituted or substituted; and formula (b); wherein Y is a C2-C4 alkylene chain which contains, between constituent carbon atoms of the chain and/or at one or both ends of the chain, 1 or 2 heteroatoms selected from O, N and S, and which is unsubstituted or substituted; and R3 is an indazole group which is unsubstituted or substituted; and the pharmaceutically acceptable salt thereof have activity as inhibitors of P13K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with P13 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders. Processes for synthesizing the compounds are also described.